Drug Trial Radar · NCT06932146
A Phase 2a Study of LLX-424 in Patients With a History of Kidney Stones
Last checked: Nov 19, 2026Latest source record: Oct 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Mar 23, 2025
Primary completion
Sep 30, 2025
Study completion Sep 30, 2025
Sponsor
- Lead sponsor
- Lilac Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2a study of glycolate oxidase inhibitor LLX-424 in patients with a history of kidney stones. Eligible subjects with a history of kidney stones will be randomized to receive study drug (LLX-424 or placebo) for 8 weeks.
Conditions
- Kidney Stones
Interventions
LLX-424Drug
Tablets for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse events (TEAEs)Time frame: From the first dose and for up to 9 weeks
- Percentage of subjects with study drug-related severe laboratory-based AEsTime frame: From the first dose and for up to 9 weeks
- QT interval on ECGTime frame: From the first dose and for up to 9 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Clinical Research Site #2
Saint Paul, Minnesota
Clinical Research Site #3
Springfield, Missouri
Clinical Research Site #1
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.